E7046 NEW
| Price | $48 | $68 | $130 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-27 |
Product Details
| Product Name: E7046 | CAS No.: 1369489-71-3 |
| Purity: 99.86% | Supply Ability: 10g |
| Release date: 2026/07/27 |
Product Introduction
Bioactivity
| Name | E7046 |
| Description | E7046 is a specific, orally bioavailable EP4 antagonist (IC50: 13.5 nM, Ki: 23.14 nM), exhibiting anti-tumor activities. |
| In vitro | Through selective EP4 antagonism, E7046 reverses the immunosuppressive effects of PGE2 on activation and differentiation of human myeloid cells [1]. |
| In vivo | E7046 (150 mg/kg) inhibits the growth of multiple syngeneic tumor models. The blockade of EP4 signaling promotes anti-tumor DC differentiation and slows tumor growth in mice. E7046 treatment reduces the growth or even rejected established tumors in vivo in a manner dependent on both myeloid and CD8C T cells [1]. In the CT-26 tumor model, the E7046/RT combination causes the anti-tumor memory response of 9 animals. In the 4T1 model, the combination of E7046 and RT also produces significantly better tumor growth inhibition activity compared with each treatment alone. The combination significantly improves survival by inhibiting the subsequent spontaneous lung metastasis of 4T1 tumors [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (20.69 mM), Solution. 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 3.3 mg/mL (6.83 mM), Sonication is recommended. 10% DMSO+90% Saline : < 10 mg/mL (20.69 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. DMSO : 235 mg/mL (486.14 mM), Sonication is recommended. |
| Keywords | ProstaglandinReceptor | Prostaglandin Receptor | Inhibitor | inhibit | EP4 | E-7046 | E7046 | E 7046 |
| Inhibitors Related | Angoroside C | Ufenamate | Pranoprofen | Tranilast | Tetrahexyldecyl ascorbate | Rutin | Ozagrel | Rebamipide | Evodiamine | Lornoxicam | Nepafenac | p-Hydroxycinnamic acid |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY